-
The huge acquisition has led to the "wind" of epigenetics, and the domestic pioneer Sailan Pharmaceutical is expected to "hold the bull's ear"
Time of Update: 2023-01-01
Based on the new generation of epigenetic mechanisms and epigenomics achievements, the company develops innovative therapeutic drugs and diagnosis and treatment methods to meet the medical needs of patients in China and around the world for major diseases such as tumors.
-
The next 5 billion potential item to go overseas may come from Biotech, the richest man
Time of Update: 2023-01-01
It is also worth noting that as a new generation of VEGFR inhibitors, fruquintinib solves the toxicity of the first generation of products, so that it can be combined with PD-1 to deploy multiple solid tumor cancers, and is expected to hit a peak of 7-800 million US dollars in the future with breakthroughs in overseas markets.
-
Q3, AI pharmaceutical industry pattern and financing profile
Time of Update: 2023-01-01
The global AI pharmaceutical landscapeThe global AI pharmaceutical landscapeAI pharmaceutical companies conduct AI pharmaceutical research and development by providing outsourcing services for pharmaceutical companies and CROs, or independently promoting their own pipelines, trying to overcome problems in the fields of cancer, psychiatric diseases, cardiovascular and cerebrovascular diseases, liver, kidney, gastrointestinal diseases, and respiratory diseases, and discovering new drugs.
-
Analysis of private placement of biopharmaceutical listed companies in recent years
Time of Update: 2023-01-01
Figure 2 Distribution of biopharmaceutical listed companies issuing private placement plans by industry segments (statistical period: 2020-October 31, 2022) Data source: Kangcheng Investment and WindThe price of the private placement is the focus of all market participants.
-
Multiple megacities epidemic prevention "reduction", will relaxation pay a high price?
Time of Update: 2023-01-01
On November 29, the joint prevention and control mechanism of the State Council issued the "Work Plan for Strengthening the Vaccination of the Elderly against the New Coronavirus", requiring a variety of measures to accelerate the vaccination rate of people over 80 years old and continue to increase the vaccination rate of people aged 60 to 79.
-
Annual Inventory: Top 10 M&A Transactions in the Global Healthcare Sector in 2022
Time of Update: 2023-01-01
6 billion US dollars, of which CSL, a leading Australian blood product and vaccine company, acquired Vifor for 117 US dollars Pharma became the largest M&A event of the year, with Pfizer, United Health and GlaxoSmithKline accounting for 70% of the top 10 M&A events.
-
After 1,000 drugs, the FDA issued a document introducing the new measures... Global regulatory dynamics
Time of Update: 2023-01-01
Take advantage of DARWIN EU studies the epidemiology of rare blood cancers; Use of sodium valproate drugs; and antibiotic use (providing insights into efforts to fight microbial resistance)Related Links:Related Links: The European Medicines Agency (EMA) has announced the selection of the first data partners for its DARWIN EU project.
-
mRNA cancer vaccine presses the accelerator button, how is the progress of domestic enterprises catching up with learning?
Time of Update: 2023-01-01
"Wang Hai's team of the National Nano Center makes new breakthroughs in tumor nanovaccines", BioWorld, 2022-11-23 In fact, the three major mRNA giants BioNTech, Moderna, CureVac and some domestic mRNA companies, as early as before the development of new crown vaccines, mainly promoted therapeutic cancer vaccines as core projects of their respective mRNA technologies.
-
Can the concept of "new crown miracle drug" ursodeoxycholic acid set off a new round of research and development?
Time of Update: 2022-12-30
On December 5, researchers at the University of Cambridge in the United Kingdom published an article in the journal Nature called "FXR inhibition may protect from. " SARS-CoV-2 infection by reducing A
-
8 to 3! FDA experts oppose the launch of heart failure drugs
Time of Update: 2022-12-30
Mistar Pharmaceuticals currently owns omecamtiv Mecarbil's commercial interests in Greater China Reference source: Reference source: Overall, the FDA's concern about whether the benefits outweigh the risks is the main reason for this rejection, and it is believed that Cytokinetics can pass smoothly if it changes its dosing strategy.
-
In vivo gene editing therapy: the rise of the country is now
Time of Update: 2022-12-30
December 20, 2022 / PharmaBIGStar News/-- As a multifunctional gene editing technology, CRISPR has brought unlimited imagination to gene therapy, and in recent years, the practice of modifying target
-
2022, Survival Atlas of PD-(L)1 in China
Time of Update: 2022-12-30
Indications "Exclusivity"In terms of indications "broad (large indications)",Indications "Broad (large indications)"Innovent (Cindilimab) includes two lung cancers, one liver cancer, and one gastric cancer;BeiGene (tislelizumab) includes three lung cancers, one liver cancer;Hengrui Pharma (carrelizumab) includes two lung cancers and one liver cancer;Junshi Biologics (teripulimab) includes one count of lung cancer;Specific number of indications:Specific number of indications:Different from the world, in the Chinese market, entering medical insurance is an important way to achieve rapid product volume.
-
Just landed overseas and pulled back to China, antigen reagents from "abandoned" to "altar" roller coaster
Time of Update: 2022-12-30
" ” In mid-December 2022, a plane transporting new crown antigen reagents exported abroad by a domestic manufacturer had just arrived at an overseas airport, and the goods had not yet had time to unload, and the whole antigen was required by the manufacturer to be shipped back to China - the reason is that China's antigen demand has exploded, and a box of difficult to find has emerged, and relevant government departments have begun to requisition antigen manufacturers' products.
-
40% of innovators block generic drugs by developing new formulations
Time of Update: 2022-12-30
In order to extend the life cycle of their products and block competition in generic drugs, original (patented) drug companies can "modify" existing drugs that have been approved for marketing through channels such as new formulations (such as new dosage forms, new compounds).
-
CSCO-CDE session: Antitumor drug involution is in remission | first scene
Time of Update: 2022-12-30
At present, the research and development of anti-tumor drugs in China is in a period of vigorous development. According to the drug clinical trial registration and information disclosure platform, the
-
【Hot spot】Just now, Academician Zhong Nanshan's lecture brushed the screen! Respond to hot topics!
Time of Update: 2022-12-30
Zhong Nanshan said that in contrast, the incubation period in the north is further shortened, sometimes symptoms appear after the second day of exposure, most people do not have obvious symptoms after infection, and some people have dry throat headache and fever.
-
Annual Inventory In 2022, these 14 Class 1 new drugs were approved in China
Time of Update: 2022-12-30
First-line treatment of inoperably advanced or metastatic squamous non-small cell lung cancer (NSCLC) significantly prolongs PFS in patients with higher ORR and longer duration of response (DoR)Pfizer: AlbuxitinibPfizer: AlbuxitinibMode of action: JAK1 inhibitorMode of action: JAK1 inhibitorIndications: atopic dermatitisIndications: atopic dermatitisIn April this year, Pfizer's oral JAK1 inhibitor albuxitinib tablets were approved for marketing in China for the treatment of moderate to severe atopic dermatitis in adults.
-
Tens of billions of gold track, BTK inhibitor research and development ushered in a new strategy
Time of Update: 2022-12-30
At present, its R&D strategy mainly includes the development of non-covalent BTK inhibitors and BTK PROTACs. 01 Non-covalent BTK inhibitors01 Non-covalent BTK inhibitorsNon-covalent BTK inhibitors do not rely on binding to the C481 site, but bind to the BTK protein by hydrogen bonding, so they are expected to effectively overcome the resistance problems in the previous generation of products.
-
Annual inventory: the world's top ten new blockbuster innovative drugs in 2022
Time of Update: 2022-12-30
Indications:On January 28, 2022, the FDA approved the marketing of Roche's new drug Vabysmo, and in September of the same year, based on the good results of phase III clinical trials, the European Commission (EC) also approved the marketing of the drug for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME), thereby improving vision to some extent.
-
10 times in 6 years! China's immuno-oncology trial has been twice that of the United States, CD19 collection "four King Kong", PD-(L)1 both China and the United States, what is the difference between the top 10 popular targets?
Time of Update: 2022-12-30
PD-(L)1 has been the hottest target in recent years, and nearly 20 PD-(L)1 monoclonal antibody drugs have been approved for marketing worldwide since 2014.
PD-(L)1 has been the hottest target in recent years, and nearly 20 PD-(L)1 monoclonal antibody drugs have been approved for marketing worldwide since 2014.
